The Union Ministry of Health and Family Welfare has proposed amendments to the Drugs Rules, 1945, to introduce a separate licensing framework for the wholesale of bulk drugs, including active and inactive pharmaceutical substances.
The proposed amendments, outlined in Draft Gazette Notification G.S.R. No. 987 (E), dated November 2, 2026, seek to introduce a separate application form (Form 19-BC) and licence form (Form 20-BC) for bulk drug wholesalers, distinct from the existing licensing provisions for pharmaceutical formulations.
Currently, a common licence covers the wholesale of both formulations and bulk drugs. The proposed changes aim to establish a dedicated regulatory framework for bulk drugs to ensure more focused oversight and greater accountability across the pharmaceutical supply chain.
The proposal was approved by the Drugs Consultative Committee (DCC) at its 67th meeting held on November 17, 2025, and by the Drugs Technical Advisory Board (DTAB) at its 93rd meeting on February 16, 2026.
Under the proposed framework, the licence will specify the categories of bulk drugs handled by wholesalers, including substances covered under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985. The wholesale sale of bulk drugs will also be required to take place under the personal supervision of a competent person.
According to the ministry, the proposed amendments are aimed at strengthening regulatory control over the wholesale distribution of bulk drugs, improving enforcement measures related to antimicrobial resistance and monitoring the movement of drugs covered under the NDPS Act.
The changes will also make it mandatory for bulk drug wholesalers to obtain a separate licence for their operations.
To ensure a smooth transition, existing licensees will be given adequate time to comply with the revised requirements. The new provisions will become applicable to them upon the expiry of their current licence retention period or 12 months after the final publication of the amendment, whichever is later.
The ministry has invited objections and suggestions from stakeholders and members of the public within 30 days from the date on which copies of the Gazette notification containing the draft rules are made available to the public.
Submissions can be sent to the Under Secretary (Drugs), Ministry of Health and Family Welfare, Government of India, U-6, Work Hall, C Wing, First Floor, Kartavya Bhawan-1, New Delhi–110001, or via email at drugsdiv-mohfw@gov.in.
-PIB


